The NM_000152.5:c.1000G>T variant in GAA is a missense variant predicted to cause substitution of glycine by cysteine at amino acid 334 (p.Gly334Cys). It has been reported in two individuals in the literature with infantile-onset Pompe disease, at least one of whom is receiving enzyme replacement therapy (PMIDs: 28196920, 39835171) (PP4_moderate). Both individuals were compound heterozygous for the variant and c.[271G>A, 307T>G] p.[Asp91Asn, Cys103Gly], phase unreported; c.307T>G (p.Cys103Gly) is classified as pathogenic by the ClinGen LD VCEP (PM3). This variant has also been reported in infantile-onset Pompe disease in the Pompe Variant Database (PMIDs: 31342611, 33560568). The highest population minor allele frequency in gnomAD v4.1.0. is 0.0000025 (3/1180038 alleles) in the Non-Finnish European population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). When expressed in HEK293 cells using a previously published in vitro assay (PMID: 36246652), GAA enzyme activity was undetectable when compared to wild type and no GAA protein was detectable on western blot (unpublished data) (PS3_moderate). The computational predictor REVEL gives a score of 0.854, which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID: 284864). In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PP4_moderate, PM3, PS3_moderate, PM2_supporting, PP3. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel, Sept. 2, 2025)